LG Chem revises licensing deal with US firm for obesity drug

Korea Times News ·
Business Corporate South Korea

LG Chem, Korea's leading chemical company, said Tuesday it has amended an exclusive license agreement with the U.S.-based Rhythm Pharmaceuticals for the development and commercialization of an obesity treatment. The amendment covers Bivamelagon, an investigational oral small-molecule melanocortin-4 receptor (MC4R) agonist, increasing the total contract value from $305 million to $855 million, the…

Read original article on Korea Times News →

Related news